Search - tctmd.com

Displaying 101 - 120 of 164

Sort: Relevancy | Date

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

Rivaroxaban-Aspirin Combo Works in ASCVD Across BMI Groups

Todd Neale

February 01, 2021

News Daily News

New Advanced Training Outlined for Future Vascular Medicine Specialists

Michael O'Riordan

January 21, 2021

News Daily News

CAC Screening Cost-effective for Statin Decisions in Hereditary CAD

Michael O'Riordan

January 14, 2021

News Daily News

Fewer Diagnostic Tests, Higher CV Mortality During COVID-19 Pandemic

Michael O'Riordan

January 12, 2021

News Daily News

Checklist for Same-Day Discharge PCI Stresses Buy-In, and a Plan

Shelley Wood

January 07, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

Shelley Wood

October 01, 2020

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Daily News

Most Stable Angina Patients Not Taking First-line Meds

Shelley Wood

June 18, 2020

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Shelley Wood

February 14, 2020

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Caitlin E. Cox

February 07, 2020

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

Advertisement

Observational Study Supports Continuing Oral Anticoagulation During PCI

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Rivaroxaban-Aspirin Combo Works in ASCVD Across BMI Groups

New Advanced Training Outlined for Future Vascular Medicine Specialists

CAC Screening Cost-effective for Statin Decisions in Hereditary CAD

Fewer Diagnostic Tests, Higher CV Mortality During COVID-19 Pandemic

Checklist for Same-Day Discharge PCI Stresses Buy-In, and a Plan

TCTMD’s Top 10 Most Popular Stories for September 2020

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Most Stable Angina Patients Not Taking First-line Meds

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content